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GLP-1 is an intestinal hormone with widespread
actions on metabolism. Therapies based on GLP-1
are highly effective because they increase glucose-
dependent insulin secretion in people with type 2
diabetes, but many reports suggest that GLP-1 has
additional beneﬁcial or, in some cases, potentially
dangerous actions on other tissues, including the
heart, vasculature, exocrine pancreas, liver, and
central nervous system. Identifying which tissues
express the GLP-1 receptor (GLP1R) is critical for
the development of GLP-1–based therapies. Our
objective was to use a method independent of
GLP1R antibodies to identify and characterize the
targets of GLP-1 in mice. Using newly generated
glp1r-Cre mice crossed with ﬂuorescent reporter
strains, we show that major sites of glp1r expression
include pancreatic b- and d-cells, vascular smooth
muscle, cardiac atrium, gastric antrum/pylorus,
enteric neurones, and vagal and dorsal root
ganglia. In the central nervous system, glp1r-
ﬂuorescent cells were abundant in the area
postrema, arcuate nucleus, paraventricular
nucleus, and ventromedial hypothalamus. Sporadic
glp1r-ﬂuorescent cells were found in pancreatic
ducts. No glp1r-ﬂuorescence was observed in
ventricular cardiomyocytes. Enteric and vagal
neurons positive for glp1r were activated by GLP-1
and may contribute to intestinal and central
responses to locally released GLP-1, such as
regulation of intestinal secretomotor activity and
appetite.
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GLP-1 is one of several metabolically active peptides that
are released from enteroendocrine cells in the gut epi-
thelium after food intake. Together with glucose-
dependent insulinotropic polypeptide (GIP), GLP-1
accounts for up to 70% of meal-stimulated insulin se-
cretion in a phenomenon known as the incretin effect.
Therapies based on GLP-1 were developed originally on
the basis that they enhance insulin secretion in people
with type 2 diabetes, but are now known also to lower
glucagon levels, slow gastric emptying, and reduce ap-
petite (1). More surprising are reports that GLP-1
improves memory and learning (2), is cardioprotective
during myocardial ischemia (3), promotes hepatocyte
function (4), and increases pancreatic exocrine
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hyperplasia (5). A critical obstacle to distinguishing direct
from indirect effects of GLP-1, however, is our in-
complete understanding of which cell types express
receptors for GLP-1 (6).
The GLP-1 receptor (GLP1R) was cloned originally
from pancreatic b-cells, where it is coupled to cyclic
adenosine monophosphate (cAMP) production and
enhanced glucose-dependent insulin release (7). GLP1R
is a high-afﬁnity receptor for “active” GLP-1, a term
encompassing GLP-1(7-36)amide and GLP-1(7-37) that
are released postprandially from enteroendocrine
L-cells in the epithelium of the small and large intestine
(8). Although believed to target b-cells through the
bloodstream, GLP-1 is rapidly cleaved and inactivated
by dipeptidyl peptidase 4 (DPP4) (9) once it enters the
circulation. This has led to the idea that receptors
located close to L-cells may act as local sensors of en-
dogenous GLP-1 before it is inactivated. One proposed
signaling route involves GLP1R located on branches of
the afferent vagus nerve innervating the portal vein
(10). Some reports suggest that DPP4-cleaved GLP-1
may also be a weak partial agonist or antagonist of
GLP1R (11), eliciting physiological responses such as
vasodilation (12). Elucidating the actions of GLP-1 and
its metabolites is critical for our understanding
of postprandial physiology and the pharmacology
of clinically approved GLP-1 mimetics and DPP4
inhibitors.
Identifying which tissues and cell types express
GLP1R faces the obstacle that many existing antibodies
to GLP1R lack speciﬁcity (6). The objective of this study
was to identify and characterize targets of GLP-1 by
a method independent of the use of antibodies and to
investigate whether glp1r is expressed in cells located
close to enteroendocrine cells. For this purpose, we
generated a transgenic mouse model in which the glp1r
promoter drives Cre recombinase. By cloning Cre into the
coding sequence of glp1r in a bacterial artiﬁcial chromo-
some (BAC), we aimed to retain the receptor promoter,
together with long 59 and 39 sequences, and achieve cell-
speciﬁc expression mirroring that of native glp1r. When
crossbred with ﬂoxed reporter strains, these mice pro-
duce offspring expressing ﬂuorescent markers in target
tissues that currently, or during development, express
glp1r.
RESEARCH DESIGN AND METHODS
Animals
Animal procedures were approved by the local ethics
committee and conformed to United Kingdom Home
Ofﬁce regulations. Mice were killed by cervical disloca-
tion, and the various tissue types were collected into ice-
cold Leibovitz-15 (L-15) medium (unless otherwise
stated, all chemicals were supplied by Sigma-Aldrich,
Poole, U.K.). Ganglia were collected directly into 4%
paraformaldehyde for immunohistochemistry.
Generation of Mice
To express Cre recombinase under the control of the
glp1r promoter, we replaced the sequence between the
start codon in exon 1 and the stop codon in exon 13 in
the murine-based BAC RP23-408N20 (Children’s Hospi-
tal Oakland Research Institute, Oakland, CA) initially by
a counter-selection cassette rpsL-neo (Gene Bridges,
Heidelberg, Germany) and subsequently by the improved
Cre (iCre) sequence (13) using Red/ET recombination
technology (Gene Bridges) (Fig. 1A). Brieﬂy, the rpsL-neo
or iCre sequences were ampliﬁed by PCR adding glp1r-
gene speciﬁc 39 and 59 sequences (see oligonucleotides in
Supplementary Table 1), and homologous recombination
was achieved upon cotransforming the BAC containing
Escherichia coli DH10B clone with the PCR product and
the plasmid pSC101-BAD-gbaA, which provides the re-
combination enzymes (Gene Bridges). Positive recombi-
nants were isolated using appropriate antibiotic selection
and characterized by PCR and restriction analysis. Iden-
tity and correct positioning of the introduced iCre se-
quence was conﬁrmed by direct sequencing using the
oligonucleotides in Supplementary Table 1. BAC DNA for
microinjection was puriﬁed using the large-construct
Maxi-Prep kit (Qiagen, Manchester, U.K.) and dissolved
at ;1–2 ng/mL in injection buffer containing (mmol/L):
10 Tris-HCl (pH 7.5), 0.1 EDTA, 100 NaCl, 0.03 sper-
mine, and 0.07 spermidine. Pronuclear injection into ova
derived from C57B6/CBA F1 parents and reimplantation
of embryos into pseudopregnant females was performed
by the Central Biomedical Services at Cambridge Uni-
versity. DNA of pups was isolated from ear clips by
proteinase K digestion and screened for the transgene by
PCR using the following primer pairs (Supplementary
Table 1): GLP1R-001/Cre001 (462 bp) and Cre002/003
(537 bp) duplexed with RM41/42 (220 bp), which
ampliﬁes a b-catenin sequence used as a DNA quality
control. The founder strain was backcrossed for more
than eight generations onto a C57B6 background. The
Cre-reporter transgenes used in the study, Rosa26–tandem-
dimer red ﬂuorescent protein (tdRFP) or –enhanced yellow
ﬂuorescent protein (EYFP), also on a C57B6 background,
were screened for with the PCR primers tdRFP sense/anti
(726 bp) and green ﬂuorescent protein (GFP)002/003
(470 bp), respectively.
Flow Cytometry
Pancreatic islets were isolated and dispersed as de-
scribed previously (8). Cell suspensions were separated
by ﬂuorescence-assisted cell sorting (FACS) using
a MoFlo Beckman Coulter Cytomation sorter (Beckman
Coulter, Inc., Hialeah, FL) or analyzed using a BD
LSRFortessa analyzer (BD Biosciences, San Jose, CA).
Side scatter (SSC), forward scatter, and pulse-width gates
were used to exclude debris and aggregates. Islet pop-
ulations were sorted into RNAse-free collection buffer for
mRNA analysis, or into protein lysis buffer (50 mmol/L
Tris-HCl, 150 mmol/L NaCl, 1% IGEPAL-CA 630, 0.5%
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deoxycholic acid, and 1 tablet of complete EDTA-free
protease inhibitor cocktail [Roche]) for measurement of
GLP-1 content by MSD total and active GLP-1 assays
(Mesoscale Discovery, Rockville, MD). FACS-analyzed
samples were processed using FlowJo 7.6 software.
Quantitative RT-PCR
RNA from homogenized tissues was extracted using TRI
Reagent or the RNeasy Micro Kit (Qiagen). RNA was
treated with DNAse I (Ambion), and reverse transcribed
according to standard protocols. Quantitative (q)RT-
PCR was performed as described previously (8) using
primers/probes as indicated in Supplementary Table 1.
Expression of the test gene was measured relative to
that of actb measured in parallel in the same sample
using the DCt method. Data are presented as 2DCt, with
the upper SEM calculated from the SEM of the DCt
data.
Immunohistochemistry
Tissues were ﬁxed in 4% paraformaldehyde, dehydrated
in 15% and 30% sucrose, and frozen in optimal cutting
temperature embedding media (CellPath, Newtown,
U.K.). Cryostat-cut sections (6–10 mm) were mounted
directly onto polylysine-covered glass slides (VWR,
Leuven, Belgium). Slides were incubated for 1 h in
blocking solution containing 10% goat or donkey
serum and overnight in PBS/0.05% Triton X-100/10%
serum with primary antisera of interest (Supplementary
Table 1). Sections were washed with PBS and incubated
with appropriate secondary antisera (donkey or goat
AlexaFluors 488, 546, 555 or 633; Invitrogen) diluted
1:300. Control sections were stained with secondary
antisera alone. Sections were mounted with Prolong Gold
(Life Technologies) before confocal microscopy (Zeiss
LSM 510, Carl Zeiss, Cambridge, U.K.).
Immunoﬂuorescence of Brain Sections
Mice under ketamine and medetomidine anesthesia were
perfused transcardially with 4% formaldehyde in PBS
(pH 7.4). Brains were removed, postﬁxed overnight in
the same ﬁxative, and cryoprotected in 30% sucrose.
Coronal sections were cut to 30 mm using a cryostat and
washed in 0.1 mol/L phosphate buffer (PB; pH 7.4). After
incubation in blocking buffer containing 10% sheep se-
rum and 0.1% Triton X-100 diluted in 0.1 mol/L PB for
30 min at room temperature, sections were transferred
to 1:1000 anti-DsRed (Clontech #632496) in blocking
buffer and incubated overnight on a shaker at 4°C. Sec-
tions were washed three times in PB and incubated with
1:500 Cy3-conjugated anti-rabbit secondary antibody
(Sigma-Aldrich #C2306) in blocking buffer for 2 h on
a shaker at room temperature. Sections were washed in
PB, mounted onto slides, and air dried before being
coverslipped and viewed using epiﬂuorescence (Eclipse
80; Nikon, Kingston upon Thames, U.K.). Photomicro-
graphs were taken with a Micropublisher 3.3 RTV camera
Figure 1—Glp1r-Cre transgenic mice labeled pancreatic b- and
d-cells. A: Schematic depicts the insert of the BAC RP23-408N20
and replacement of the glp1r coding region from exons (ex) 1–13
with iCre. Lengths (in kb) of the murine genomic sequence 39 and
59 of the glp1r coding region in the BAC are indicated. B: Dis-
persed pancreatic islet cells from glp1r-Cre/ROSA26-YFP mice,
analyzed by FACS. Green (yellow) ﬂuorescence was measured by
excitation at 488 nm and emission at 530/20 nm and is plotted
against forward scatter in arbitrary units (AU). C: Cells with high red
ﬂuorescence from glp1r-Cre/ROSA26-tdRFP mice were FACS
separated into populations with low and high SSC. These were
analyzed by qRT-PCR for expression of hormones (D) or glp1r (E ).
n = 3 each; **P < 0.01 by Student t test. Fixed pancreatic slices
were coimmunostained RFP or YFP (representing glp1r ﬂuores-
cence) together with glucagon and insulin (*indicates a cell triple-
positive for glucagon, insulin, and glp1r ﬂuorescence) (F ) or so-
matostatin (G). Nuclei are visualized with Hoechst stain.
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and QCapture Pro software (QImaging, Inc., Surrey, BC,
Canada).
Nodose and Enteric Ganglia Culture
Nodose ganglia (NG) were transferred into Dulbecco’s
modiﬁed Eagle’s medium (DMEM) containing 1 mg/mL
collagenase type 1 and trypsin (Worthington Biochemical
Corp., Lakewood, NJ). For enteric ganglia culture, the
small intestinal muscle layer was minced and digested in
DMEM containing 1.5 mg/mL collagenase I and 1.3 mg/mL
trypsin. All ganglia were digested for 1 h at 37°C and
dissociated by trituration. Cells were plated on
polylysine-coated dishes, and after attachment, dishes
were ﬂooded with DMEM supplemented with 10% (v/v)
FBS, 100 units/mL penicillin, 0.1 mg/mL streptomycin,
and 50 ng/mL nerve growth factor. Calcium imaging
and electrophysiology were performed within 48 h of
dissociation.
Calcium Imaging
NG cultures were loaded in 2 mmol/L Fura-2-acetox-
ymethyl ester (Invitrogen, Life Technologies, Paisley, U.K.)
for 30 min in standard saline solution containing (mmol/L)
4.5 KCl, 138 NaCl, 4.2 NaHCO3, 1.2 NaH2PO4, 2.6 CaCl2,
1.2 MgCl2, 5 glucose, and 10 HEPES (pH 7.4, NaOH).
Imaging was performed as described previously (8).
Fura2 was excited at 340 and 380 nm and RFP at 555 nm.
Fura2 ﬂuorescence measurements were taken every 3 s,
and the background was corrected and expressed as the
340-to–380-nm ratio. Average ﬂuorescence ratios were
determined over 20 s, and responses were expressed as
the maximum ratio achieved during stimulation divided
by the mean of the ratios measured before and after
washout. Cells were included in the analysis if they
responded to 30 mmol/L KCl.
Nested PCR
After digestion and trituration, small enteric ganglia were
picked using a glass capillary pipette ﬁlled with RNAse-
free PBS. The pipette tip was crushed into RNAse-free
collection buffer (4 mL First Strand Buffer [Invitrogen,
U.K.], 4 mL RNAse-free water, and 1 mL RNAseOUT).
Samples were reverse-transcribed using SuperScript III
(Invitrogen, U.K.) using standard protocols. Actb and
glp1r were ampliﬁed by multiplex nested PCR using
25 cycles each and the primers given in Supplementary
Table 1.
Electrophysiology
Experiments were performed on identiﬁed RFP-positive
cells in 12- to 48-h-old cultures containing partially dis-
sociated enteric ganglia from glp1r-Cre/ROSA26-tdRFP
mice. Microelectrodes were pulled from borosilicate glass
(GC150 TF-15; Harvard Apparatus, Kent, U.K.) and the
tips coated with reﬁned yellow beeswax. Pipette solution
contained (mmol/L) 107 KCl, 1 CaCl2, 7 MgCl2, 11 EGTA,
10 HEPES, and 5 K2ATP (pH 7.2 KOH). Membrane po-
tential was recorded using a Axopatch 200B and pCLAMP
software (Molecular Devices, Berkshire, U.K.) in the
standard whole-cell patch conﬁguration at room tem-
perature. Cells were perfused with standard saline solu-
tion (see above), to which GLP-1 was added as indicated.
Data Analysis
Data are presented as mean 6 SEM. Statistical analysis
was performed using Microsoft Excel and GraphPad
Prism 5.0 software. Data that were normally distributed
were analyzed by Student t test or ANOVA with post hoc
Bonferroni test, as indicated in the f igure legends. Cal-
cium imaging and electrophysiology data were analyzed
with the nonparametric tests, Mann-Whitney, or Wil-
coxon rank sign test, as indicated, with a threshold for
signiﬁcance of P , 0.05.
RESULTS
Two glp1r-Cre founder strains containing the transgenic
constructs depicted in Fig. 1A were generated and
crossed with a ROSA26-tdRFP reporter (14). Tissues/cells
in which the ﬂuorescent reporter is visible directly or by
immunostaining are described here as exhibiting glp1r
ﬂuorescence. One founder strain showed sparse glp1r
ﬂuorescence in pancreatic islets and was discontinued.
The other showed marked islet ﬂuorescence consistent
with the known expression of glp1r in b-cells and was
used for all analyses. It was crossed with a ROSA26-YFP
reporter strain to generate mice producing YFP in glp1r-
expressing cells and with GLU-Venus (8) to enable the
colabeling of pancreatic a-cells and enteroendocrine
L-cells that make glucagon/GLP-1.
Glp1r in the Pancreas
FACS analysis of pancreatic islet cell suspensions
revealed a glp1r-ﬂuorescent population (Fig. 1B) that
could be divided into two groups with distinct SSC
(Fig. 1C). These were separated by FACS, analyzed for
expression of ins, gcg, sst, and ppy by qRT-PCR, and found
to correspond to b-cells (high SSC) and d-cells (low SSC)
(Fig. 1D). Expression of glp1r in both populations was
conﬁrmed by qRT-PCR (Fig. 1E) and was;10-fold lower in
d-cells than in b-cells (P = 0.006). Colocalization of glp1r
ﬂuorescence with insulin or somatostatin immunostaining
was also evident in pancreatic slices (Fig. 1F and G).
To investigate expression of glp1r in a-cells, we ex-
amined pancreata from glp1r-Cre/ROSA26-tdRFP/GLU-
Venus mice, in which a-cells are additionally labeled with
Venus. By FACS analysis, only 9.5 6 1.4% of a-cells
(n = 11) were glp1r-ﬂuorescent, consistent with the low
expression of glp1r in the total a-cell population (Fig. 2A)
and our previous detection of GLP1R immunoﬂuores-
cence in a small proportion of a-cells (15). The pop-
ulation of a-cells exhibiting glp1r ﬂuorescence was found
by qRT-PCR to express gcg, as predicted, but also had
signiﬁcantly more ins than their non–glp1r-ﬂuorescent
a-cell counterparts (Fig. 2B). Rare cells immunopositive
for insulin, glucagon, and glp1r-RFP were correspond-
ingly identiﬁed in tissue slices (see cell marked with
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asterisk in Fig. 1F). However, single- and double-
ﬂuorescent a-cells both contained very little active GLP-1
(Fig. 2C):;1.5 pg/1,000 a-cells compared with;650 pg/
1,000 colonic L-cells (8).
In pancreatic slices, glp1r ﬂuorescence was also evi-
dent in nonislet structures. Predominant labeling was
observed in blood vessels, as similarly observed in other
tissues (Fig. 2D and Fig. 3). Costaining with an antibody
against cytokeratin revealed a few scattered glp1r-ﬂuorescent
cells in pancreatic ducts (Fig. 2E and F).
Glp1r in the Cardiovascular System
Prominent glp1r-ﬂuorescent labeling was observed in the
aorta (Fig. 3A) and in arteries and arterioles in a range of
tissues, including the heart, kidney, pancreas, and in-
testine (Fig. 3). Glp1r mRNA was correspondingly
detected in aorta by qRT-PCR (Fig. 3B). In the kidney
(Fig. 3C), glp1r ﬂuorescence was found in arterioles and
colocalized with smooth muscle a-actin (a-SMA) and the
pericyte marker NG2, suggesting the labeling of smooth
muscle cells. Overlap of glp1r ﬂuorescence with immu-
nostaining for renin was also observed. In the intestine,
many small blood vessels were glp1r-ﬂuorescent and
exhibited colocalization with a-SMA and NG2 (Fig. 3D
and E). In tissue preparations where small veins could be
seen lying adjacent to arterioles, glp1r ﬂuorescence
appeared restricted to the arterial circulation (Fig. 3F).
Ventricular myocardium was devoid of glp1r ﬂuores-
cence, with the exception of vascular structures immuno-
positive for a-SMA (Fig. 3G). In line with a recent report
(16) that GLP-1 stimulates secretion of atrial natriuretic
factor, scattered glp1r-ﬂuorescent cells were found
throughout the atrial myocardium (Fig. 3H). Expression of
glp1r mRNA mirrored these ﬁndings, being approximately
sixfold higher in atrial than ventricular extracts (Fig. 3B).
Glp1r in the Central Nervous System and Afferent
Neuronal Ganglia
Sections through the hypothalamus and brainstem of
glp1r-Cre/ROSA26-tdRFP mice revealed RFP-positive
cells in the area postrema, arcuate nucleus, ventromedial
hypothalamus, and paraventricular nucleus (Fig. 4A),
consistent with previous reports (17). Glp1r-ﬂuorescent
cell bodies and glp1r mRNA were found in ganglia of the
Figure 2—Glp1r in pancreatic a-cells. A: Islet cells from glp1r-Cre/ROSA26-tdRFP/GLU-Venus mice, analyzed by FACS to show red
ﬂuorescence (representing expression of glp1r) or green ﬂuorescence (representing expression of gcg). B: Single- or double-positive cells
were puriﬁed from Q1–Q3 marked in A, and analyzed for expression of ins and gcg by qRT-PCR. ***P < 0.001 by ANOVA with post hoc
Bonferroni test, n = 5–7. C: Active GLP-1 hormone concentrations in cells collected from different quadrants of A as indicated. Q1–4 all
islet cells, Q1 + high SSC b-cells, Q2 + Q3 all a-cells, and Q2 double-ﬂuorescent cells (mean and SEM of four FACS sorts, each of pooled
islets from one to two mice). D–F: Pancreatic sections from glp1r-Cre/ROSA26-YFP mice coimmunostained for a-SMA or cytokeratin (CK)
together with YFP. The marked area in E is shown at higher magniﬁcation in F. Q, quadrant.
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afferent vagus nerve (NG) (Fig. 4B) and dorsal root
ganglia (DRG) (Fig. 4C), although by qRT-PCR we
detected less glp1r mRNA in DRG than in NG (Fig. 4D).
Consistent with the previous detection of calcitonin
gene–related peptide (CGRP) in extrinsic sensory neu-
rons innervating the gastrointestinal tract, a small pop-
ulation of glp1r-ﬂuorescent neurons in DRGs were
immunopositive for CGRP by immunostaining (Fig. 4C).
In primary NG cultures, GLP-1 did not directly elevate
intracellular Ca2+ concentrations but enhanced Ca2+
responses to ATP in glp1r-ﬂuorescent cells, without af-
fecting ATP responses in nonﬂuorescent cells (Fig. 4E
and F). Cholecystokinin, leptin, and serotonin, by con-
trast, triggered larger Ca2+ responses in nonﬂuorescent
than in glp1r-ﬂuorescent neurons (Fig. 4G).
Glp1r in the Liver and Intestines
Hepatocytes were not glp1r-ﬂuorescent, but ﬂuorescent
ﬁbers were observed in the wall of the portal vein near
the liver hilus (Fig. 5A), consistent with previous reports
(10). Dense networks of glp1r-ﬂuorescent ﬁbers were
found in the muscular and submucosal layers of the
stomach in the vicinity of gastric pylorus (Fig. 5B and C),
in some places exhibiting colabeling with neuronal nitric
oxide synthetase (nNOS). Scattered glp1r-ﬂuorescent
neuronal ﬁbers and cell bodies were identiﬁed in the
small intestine and colon, but contrary to a recent report
(18), the epithelial layer was largely devoid of glp1r
ﬂuorescence. Glp1r mRNA was correspondingly detected
by PCR in myenteric ganglia containing glp1r-ﬂuorescent
cells (Fig. 5D). Patch clamp recordings of small intestinal
myenteric neurones in primary culture revealed that
glp1r-ﬂuorescent neurons were electrically active and
that their action potential frequency was increased by
GLP-1 (Fig. 5E and F). Two glp1r-ﬂuorescent cell pop-
ulations were distinguishable electrophysiologically by
the action potential waveform (Fig. 5G): 14 of 22 (64%)
of neurons were the synaptic (S) type and 8 (36%) were
the after-hyperpolarizing (AH) type.
Immunostaining for nNOS, a marker largely restricted
to inhibitory motor neurones, revealed that 143 of 227
(63%) of glp1r-ﬂuorescent neurones in small intestinal
cultures (Fig. 5H) and 10 of 54 (19%) in colonic cultures
(Fig. 5I) were nNOS-positive. Most nNOS-positive cell
bodies, however, were glp1r-negative (small intestine,
3,523 of 3,666 [96%]; colon, 163 of 173 [94%]).
A smaller proportion of glp1r-ﬂuorescent cells in culture
stained for calretinin (small intestine, 7 of 142 [5%];
colon, 10 of 24 [42%]; Fig. 5G and H), CGRP, or calbindin
(not shown), markers typically associated with intrinsic
primary afferent neurones. Glp1r-ﬂuorescent ﬁbers were
observed in the mucosa, in some cases relatively close to
L-cells (Fig. 5J).
DISCUSSION
Despite wide academic and commercial interest in the
actions of GLP-1, attempts to identify the cellular targets
Figure 3—Glp1r in the cardiovascular system. Sections of aorta
(A), kidney (C), intestine (D and E), and cardiac ventricle (G) or
atrium (H) from glp1r-Cre/ROSA26-YFP mice were coimmuno-
stained for YFP (representing glp1r ﬂuorescence) and a-SMA,
NG2, or renin, as indicated. In kidney sections, G depicts the
position of glomeruli. B: qRT-PCR analysis of glp1r expression
in aorta, atrium, and ventricle (geometric mean + 1 SEM, n = 5–6
each). F: Blood vessels in intestine from a glp1r-Cre/ROSA26-
tdRFP mouse: light microscopy (A, arteriole; V, venule) (upper
panel), tdRFP ﬂuorescence (lower panel).
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of GLP-1 are hampered by the lack of speciﬁcity of
antibodies to GLP1R. Our development of a new trans-
genic mouse model expressing Cre recombinase driven by
the glp1r promoter provides an antibody-independent
method for the identiﬁcation and characterization of live
cells expressing glp1r, using ﬂoxed ﬂuorescent reporter
strains. The results illuminate not only which tissues
exhibited glp1r ﬂuorescence but also those that did not.
Establishing deﬁnitively that the GLP1R protein is
produced by all glp1r-ﬂuorescent cells will be important,
because our use of Cre recombinase results in a perma-
nent activation of the ﬂuorescent reporters, even in cells
that no longer express the receptor as well as in the
progeny of cells that have once expressed glp1r. Where
neurones were identiﬁed, we were able to conﬁrm ex-
pression of GLP1R protein by demonstrating functional
responsiveness to added GLP-1. In other cases, such as
the kidney and heart, one would ideally demonstrate
costaining of glp1r-ﬂuorescent structures with antibodies
against GLP1R, but this will remain difﬁcult until better
antibodies become available. It is possible that cells
weakly expressing glp1r may generate insufﬁcient Cre
recombinase to activate the ﬂuorescent reporters. This
may explain our inability to conﬁrm a recent report that
GLP1R is located in the intestinal epithelial layer (18),
but studies relying predominantly on the use of GLP1R
antibodies should be interpreted with caution (6).
Throughout the body we observed glp1r ﬂuorescence
colocalizing with a-SMA in large and small arteries, sug-
gesting that vascular smooth muscle is a potential target
for circulating GLP-1. Consistent with these ﬁndings,
chronic treatment with GLP-1 mimetics in patients with
type 2 diabetes is associated with a small reduction in
blood pressure and an increase in heart rate (19). The
underlying physiology appears complex, however, and in
rats, GLP-1 was found to act as a vasodilator in the pe-
riphery but as a vasoconstrictor in the splanchnic bed (20).
Reports that DPP4-inactivated GLP-1 triggers vasodilation
and that not all responses to GLP-1 are lost in mice
lacking glp1r (12) have even led to the speculation that
there may exist an alternative receptor responsive to GLP-1
and/or its metabolites. The vasodilatory effect of GLP-1
in mice was recently reported to be an indirect conse-
quence of enhanced atrial natriuretic factor release (16).
In support of this idea, we found that the cardiac atrium
expressed particularly high levels of glp1r mRNA and had
scattered glp1r-ﬂuorescent cells in addition to the labeled
vasculature. We also detected glp1r ﬂuorescence in renal
arterioles and in renin-producing cells, consistent with
reports that GLP-1 has direct effects on the kidney (21).
Figure 4—Glp1r in the brain and afferent neuronal ganglia. A:
Coronal brain sections from glp1r-Cre/ROSA26-tdRFP mouse,
immunostained for RFP. In caudal brainstem (top), a high density
of ﬂuorescent cells was observed in the area postrema (AP),
whereas only few were evident in the nucleus of the solitary tract
(NTS) and dorsal vagal nucleus (DMNX), and none were found in
the hypoglossal nucleus (HN). In hypothalamus (middle and lower
panels), large numbers of RFP ﬂuorescent cells were observed in
the arcuate nucleus (ARC), ventromedial hypothalamus (VMH), and
paraventricular nucleus (PVN). 3V, 3rd ventricle; CC, central canal;
ME, median eminence. Scale bar = 150 mm. B: Section of NG from
glp1r-Cre/ROSA26-tdRFP mouse showing RFP-positive cells. C:
DRG section from a glp1r-Cre/ROSA26-tdRFP mouse costained
for RFP and CGRP. D: Whole NG or DRG were analyzed for glp1r
vs. actb expression by qRT-PCR (geometric mean + 1 SEM of
three each). E: NG from glp1r-Cre/ROSA26-tdRFP mice were
studied by Fura2 Ca2+ imaging in primary culture. Representative
trace from an RFP-positive NG neuron to ATP (0.5 mmol/L) applied
in the absence or presence of GLP-1 (1 nmol/L), as indicated by
the horizontal bars. F: Mean 340-to–380-nm ﬂuorescence ratios
from 13 RFP-positive cells (□) and 12 RFP-negative (■) cells,
monitored as in E and normalized to baseline recorded in the
absence of test agent. **P < 0.01 by Wilcoxon signed rank test. G:
Ca2+ responses of RFP-positive (□) and RFP-negative (■) cells to
cholecystokinin (CCK) (10 nmol/L), leptin (10 nmol/L), or 5HT
(10 mmol/L), normalized to baseline in control solution. From left to
right, columns represent data from n = 18, 41, 9, 31, 14, and 35
cells, respectively. *P < 0.05, ***P < 0.001 by Mann-Whitney test.
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Despite literature suggesting direct cardioprotective
effects of GLP-1, however, glp1r ﬂuorescence was not
observed in ventricular cardiomyocytes. In view of the
prominent labeling of the arterial system, it seems likely
that the reported effects of GLP-1 on cardiac function
may be mediated indirectly via the coronary vasculature.
In pancreatic islets, glp1r expression was largely re-
stricted to the b- and d-cell populations, with only ;10%
of a-cells exhibiting glp1r ﬂuorescence. The ﬁnding that
glp1r was expressed in d-cells but was largely excluded
from a-cells supports the idea that the inhibition of glu-
cagon secretion by GLP-1 is mediated indirectly through
enhanced somatostatin release (22). The role of the;10%
of a-cells that were glp1r-ﬂuorescent but apparently
expressed ins is unclear. Although we speculated that
proglucagon may be alternatively processed in a-cells
producing insulin, we found no evidence for production of
substantial amounts of active GLP-1 in the double-
ﬂuorescent a-cell or the total a-cell population. In the
exocrine pancreas, glp1r ﬂuorescence was largely conﬁned
to the vasculature, with only sporadic glp1r-ﬂuorescent
cells identiﬁable in pancreatic ducts. Whether these sparse
glp1r-positive a-cells and ductal cells are signiﬁcant tar-
gets of GLP-1 mimetics will be of interest in the context of
current concerns that incretin therapies may have adverse
effects on the pancreas, triggering a-cell hyperplasia,
pancreatitis, and pancreatic cancer (23).
In the brain stem, glp1r ﬂuorescence was prominent
in the area postrema. This is a region with a leaky blood–
brain barrier that has been postulated previously as an
area potentially capable of responding to circulating
GLP-1 concentrations (24). In the hypothalamus, we
found glp1r ﬂuorescence in the arcuate and para-
ventricular nuclei, coinciding with the sites we found
previously to receive projections from proglucagon-
producing neurones in the nucleus of the tractus solitarius
(25). These cells are therefore likely to form a component
of the relay circuit linking the brainstem to the appetite-
controlling networks of the hypothalamus.
The identiﬁcation of glp1r-ﬂuorescent neurons in the
gastric antrum and pylorus, intestine, NG, and DRG may
be relevant to understanding the local targets of in-
testinally released GLP-1. Dense innervation of the py-
lorus by glp1r-ﬂuorescent ﬁbers is consistent with the
well-recognized action of GLP-1 to inhibit gastric emp-
tying, the “ileal brake,” although further studies will be
required to elucidate the identity and origin of these
ﬁbers. Our functional analysis suggests that vagal cell
bodies expressing glp1r form a distinct neuronal pop-
ulation, responding to GLP-1 but not cholecystokinin,
leptin, or 5HT. That GLP-1 activates vagal afferent
neurons terminating in the wall of the portal vein has
been recognized for several years (10). Vagal innervation
of the intestine, however, diminishes along the length of
Figure 5—Glp1r in enteric neurons. A: Fixed-tissue section of liver from a glp1r-Cre/ROSA26-tdRFP mouse, showing glp1r ﬂuorescence
in structures surrounding a portal vein. Antral area of the stomach from a glp1r-Cre/ROSA26-tdRFP/ROSA26-YFP mouse, immunostained
for YFP (green) and a-SMA (red) (B) and for RFP (green) and nNOS (red) (C). D: Nested PCR ampliﬁcation of glp1r and b-actin, performed
on three handpicked glp1r-ﬂuorescent enteric ganglia from glp1r-Cre/ROSA26-tdRFP mice. E: Representative recording of a partially
dissociated small intestinal glp1r-ﬂuorescent enteric neuron in primary culture, monitored in whole-cell current clamp, after addition of
GLP-1 (10 nmol/L). F: Mean action potential (AP) frequency of seven cells under basal conditions and after GLP-1 application. *P < 0.05
by Wilcoxon signed rank test. G: Enteric neurons, recorded as in E, were divided into AH type (with characteristic hump on the action
potential downstroke and AH) and S type. The dashed line represents the 0 mV line. Small intestinal (H) and colonic (I) tissue sections from
a glp1r-Cre/ROSA26-tdRFP mouse costained for RFP together with nNOS or calretinin, as indicated. Because direct RFP ﬂuorescence is
lost on ﬁxation, a green secondary antibody was used to visualize RFP in the upper panels of H. J: Intestinal tissue section from a glp1r-
Cre/ROSA26-tdRFP/GLU-Venus mouse shows proximity of an L-cell (green) and a red glp1r-ﬂuorescent ﬁber.
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the gastrointestinal tract and inversely mirrors the fre-
quency of L-cells, which predominate in the distal gut.
Our identiﬁcation of glp1r-positive cell bodies in the
enteric nervous system and DRGs suggests that GLP-1
may also signal to the central nervous system through
local and spinal sensory nerves, potentially providing
a signaling route recruited by GLP-1 released more dis-
tally. Whether the glp1r-ﬂuorescent nerve ﬁbers we ob-
served in the intestinal mucosa, in some cases close to
L-cells, represent the terminals of these “sensory” neu-
rons or of enteric neurons remains to be elucidated.
Glp1r-ﬂuorescent enteric neurons in primary culture
exhibited increased ﬁring frequency on application of
GLP-1, but their functional role remains to be estab-
lished. On the basis of the reported characteristics of
guinea pig enteric neurones (26), our data suggest that
the S-type neurons may correspond to the population of
glp1r-ﬂuorescent nNOS-positive cells and might thus
play role in the local inhibition of circular and/or longi-
tudinal muscle tone. The ﬁnding of AH-type electro-
physiology in some cells and of coimmunostaining of
glp1r ﬂuorescence with calretinin, calbindin, and CGRP
suggests that there is also a population of GLP-1-
responsive intrinsic primary afferent neurones that may
relay signals to other regions of the enteric nervous
system or afferent neurons.
Glp1r-ﬂuorescent afferent and enteric neuronal cell
bodies and nerve ﬁbers within the intestinal mucosa are
of particular interest when considering the physiological
consequences of food intake and bariatric surgery. Gas-
tric bypass results in dramatically elevated GLP-1 levels,
antagonism of which largely abolishes postsurgical
improvements in glucose-stimulated insulin release (27).
GLP-1 mimetics, however, are markedly less effective
than surgery in treating type 2 diabetes. The physiolog-
ical consequences of endogenous GLP-1, released locally
at high levels after surgery and potentially reaching high
concentrations at the site of local nerve endings, clearly
deserve further attention. Current and future ﬁndings
using our new mouse model promise to improve our
understanding of the desirable and undesirable actions of
this therapeutically fascinating hormone.
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